The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...

1FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review - Valneva2Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate - Valneva3 This ...

If approved, Valneva’s shot could be the first approved for chikungunya, a virus transmitted by mosquitoes with similar symptoms to dengue and Zika, including severe joint pain that can last years.

18 Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet - Valneva 19 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine ...

6 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries 7 CEPI awards up to $23.4 million to Valneva for late-stage development ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU ...